Vitamin D (25-0H D3) status and pathological response to neoadjuvant chemotherapy in stage II/III breast cancer: Data from the NEOZOTAC trial (BOOG 10-01).

What Was Tested

This randomized controlled trial looks at Vitamin D, K2, Magnesium and Zinc.

The researchers investigated the predictive value of these levels for pathological response after neoadjuvant chemotherapy in patients with breast cancer taking part in the NEOZOTAC phase-III trial.

Who Took Part

By PubMed's age tags, the people studied were adults, middle-aged adults and older adults, women only.

The relationship between these measurements and clinical outcome, as defined by pathological complete response in breast and lymph nodes (pCR) was examined.

How the Study Was Run

In design terms this was a randomized study.

Random assignment meant chance, not the researchers, decided who got Vitamin D, K2, Magnesium and Zinc and who got the comparison, which limits bias.

Serum vitamin D was measured at baseline and before the last cycle of chemotherapy.

What Was Measured

The researchers investigated the predictive value of these levels for pathological response after neoadjuvant chemotherapy in patients with breast cancer taking part in the NEOZOTAC phase-III trial.

PubMed files the paper under topics including Breast Neoplasms, Calcifediol, Chemotherapy, Adjuvant, Disease-Free Survival, Lymph Nodes, Neoadjuvant Therapy and Neoplasm Staging.

Author keywords: 25-Hydroxy-vitamin D, Breast cancer, Neoadjuvant chemotherapy and Zoledronic acid.

What This Means in Plain Language

The paper is a randomized study of Vitamin D, K2, Magnesium and Zinc.

Its findings take up roughly 7 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2016 (Breast (Edinburgh, Scotland)), a journal based in Netherlands.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.